Skip to main content

Advertisement

SpringerLink
Log in

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD). Several studies pointed out the possible role of increased leptin in NAFLD in humans. The aim of this study is to determine the effect of metformin on plasma leptin levels in obese patients with type 2 diabetes mellitus and NAFLD compared with lifestyle interventions. Thirty-four obese patients with newly diagnosed type 2 diabetes mellitus were prospectively followed for 6 months. All patients had ultrasonographic evidence of NAFLD at baseline. The patients were randomized into two groups: group 1 (n = 15) followed lifestyle changes only and group 2 (n = 19) received metformin (1,700 mg/day). At the end of treatment, BMI, WHR, HbA1c, fasting glucose, leptin, HOMA-IR, alanine aminotransferase values decreased in both groups. No significant difference in the end-points was observed between two groups. Only in group 2, LDL decreased and HDL increased significantly. Liver echogenity decreased significantly at the end of study in both groups. The percentage of patients who no longer had evidence of NAFLD was not significantly different between the groups (20% of patients on lifestyle intervention vs. 16% of patients on metformin). The data demonstrate that, metformin and lifestyle interventions equally affected the plasma leptin levels, BMI and degree of NAFLD in obese patients with type 2 diabetes mellitus. In addition, the effects of metformin on the variables were not found to be mediated by leptin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Meigs JB (2000) Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 152:908–911

    Article  PubMed  CAS  Google Scholar 

  2. Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923

    Article  PubMed  Google Scholar 

  3. Marchesini G, Marzocchi R, Agostini F, Bugianesi E (2005) Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16:421–427

    Article  PubMed  CAS  Google Scholar 

  4. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 22:763–770

    Article  Google Scholar 

  5. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci S, Bagci S, Gulsen M, Karaeren N, Dagalp K (2000) Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95:3584–3589

    Article  PubMed  CAS  Google Scholar 

  6. Hu ZW, Guo JW, Deng XL (2006) Association of serum leptin and insulin resistance with nonalcoholic fatty liver disease. Nan Fang Yi Ke Da Xue Bao 26:853–855

    CAS  Google Scholar 

  7. Kaplan LM (1998) Leptin, obesity and liver disease. Gastroenterology 115:997–1001

    Article  PubMed  CAS  Google Scholar 

  8. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in non-alcoholic steatohepatitis. Lancet 358:893–894

    Article  PubMed  CAS  Google Scholar 

  9. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19:537–544

    Article  PubMed  CAS  Google Scholar 

  10. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M (1983) Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 139:43–50

    Article  PubMed  CAS  Google Scholar 

  11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419

    Article  PubMed  CAS  Google Scholar 

  12. Marchesini G, Brizi M, Morselli Labate AM et al (1999) Association of non-alcoholic fatty liver disease to insulin resistance. Am J Med 107:450–455

    Article  PubMed  CAS  Google Scholar 

  13. Caldwell SH, Argo CK, Al-Osaimi AM (2006) Therapy of NAFLD: insulin sensitizing agents. J Clin Gastroenterol 40(Suppl 1):S61–S66

    PubMed  CAS  Google Scholar 

  14. Kirpichnikov D, McFarlane SI, Sowers JR (2002) Metformin: an update. Ann Intern Med 137:25–33

    PubMed  CAS  Google Scholar 

  15. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 6:998–1003

    Article  PubMed  CAS  Google Scholar 

  16. Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, Bhansali A (2007) Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 6:222–226

    PubMed  CAS  Google Scholar 

  17. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082–1090

    Article  PubMed  CAS  Google Scholar 

  18. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP (2004) Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 20:23–28

    Article  PubMed  CAS  Google Scholar 

  19. Blaszyk H, Ferrentino N, Forsell S, Strader D, Lidofsky S (2005) A pilot study of metformin as treatment for nonalcoholic steatohepatitis. Gastroenterology 122:M1699

    Google Scholar 

  20. Akyuz F, Demir K, Ozdil S, Aksoy N, Poturoglu S, Ibrisim D, Kaymakoglu S, Besisik F, Boztas G, Cakaloglu Y, Mungan Z, Cevikbas U, Okten A (2007) The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci 52:2359–2367

    Article  PubMed  CAS  Google Scholar 

  21. Adams LA, Angulo P (2007) Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 11:25–35

    Article  PubMed  Google Scholar 

  22. Tasaka Y, Yanagisawa K, Iwamoto Y (1997) Human plasma leptin in obese subjects and diabetics. Endocr J 44:671–676

    Article  PubMed  CAS  Google Scholar 

  23. Adamia N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M (2007) Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 145:52–55

    PubMed  Google Scholar 

  24. Romualdi D, Campagna G, Selvaggi L Jr, Cento R, Proto C, Lanzone A, Guido M (2007) Metformin treatment does not affect total leptin levels and free leptin index in obese patients with polycystic ovary syndrome. Fertil Steril Jul 19 [Epub ahead of print]

  25. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550–554

    Article  PubMed  CAS  Google Scholar 

  26. Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA (2007) Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab 9:330–336

    Article  PubMed  CAS  Google Scholar 

  27. Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Numao T, Fukuda T, Shimada K, Kario K (2007) Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 30:23–30

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Faculty of Medicine, Baskent University, 5. sokak No: 48, Bahcelievler, 06490, Ankara, Turkey

    A. Nar

  2. Department of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, Turkey

    O. Gedik

Authors
  1. A. Nar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Gedik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Nar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nar, A., Gedik, O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 46, 113–118 (2009). https://doi.org/10.1007/s00592-008-0067-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-008-0067-2

Keywords

Search

Navigation